Funding Priority

Focus on Faculty:
Investing in the Best

We are revolutionizing the possibilities for healthcare in our research labs every day. From treatments for diseases to discoveries that spark new companies, our school is setting the example for game-changing impact. The research taking place is groundbreaking and highly collaborative.

UNC Eshelman School of Pharmacy

    Investing in the Best and Brightest

    The competition for exceptional faculty is fierce. Support for endowed professorships helps us recruit and retain world-renowned leaders who are shaping the next generation of pharmacists and contributing to humanity’s understanding of disease treatment. Angela Kashuba, Pharm.D., our John A. and Deborah S. McNeill Jr., Distinguished Professor of Pharmacy, is a perfect example of the critical role our school plays in advancing disease treatment. She chairs our Division of Pharmacotherapy and Experimental Therapeutics and directs the UNC Center for AIDS Research Clinical Pharmacology and Analytical Chemistry Core.

    Her work with this group has discovered gender differences in drug effectiveness that are game changing in optimizing antiretroviral pharmacology for the treatment, prevention and eradication of HIV. Preeminent faculty like Dr. Kashuba are translating discoveries into better education for our students, economic benefits for North Carolina and improved lives for patients worldwide.

    “The McNeill’s generosity has enabled me to create and implement ambitious plans to improve therapy for HIV treatment, prevention and cure,” Dr. Kashuba said.

    We are Revolutionizing the Possibilities for Health Care

    In a first for medical science, Shawn Hingtgen, Ph.D., turned skin cells into stem cells that hunt down and destroy brain tumors known as glioblastomas. The work represents the newest evolution of stem-cell technology. Dr. Hingtgen and his team have engineered the stem cells to deliver tumor-killing therapeutic agents. It is a breakthrough that could offer, for the first time in more than 30 years, a new and more effective treatment for the devastating disease.

    “Patients desperately need a better standard of care. This is a big step toward a real treatment and making a real difference,” said Dr. Hingtgen. He envisions the concept being adapted to fight other types of brain cancer, including pediatric cases.

    Drs. Kashuba and Hingtgen’s remarkable work attests to our ever-pressing need to support faculty research that improves outcomes and changes lives for the better.

     

    Return to main pageOpens in new window

    More UNC Eshelman School of Pharmacy Funding Priorities

    Explore Stories

    A UNC Eshelman School of Pharmacy student takes notes during class.
    Health

    Strengthening Diversity, Improving Care

    Grants to the UNC Eshelman School of Pharmacy will support diversity and rural care programs.

    Nate Hathaway in the CRISPR Screening Facility
    Research

    UNC-Chapel Hill Awarded Funding for Study of Malan Syndrome

    UNC Eshelman School of Pharmacy and CRISPR Screening Facility collaborate on Malan Syndrome study.

    Health

    Smarter Organ Transplants

    The UNC Eshelman Institute for Innovation's Venture Studio invested in technology for smarter organ transplants.

    Shawn Hingtgen and Jillian Perry
    Research

    Treating the Untreatable

    New research funded by a NIH grant seeks to combat one of the most treatment-resistant cancers

    Rebeca Stiepel
    Health

    Passion and Aptitude

    Rebeca Stiepel received the 2022 Kathryne A. Brewington Graduate Research Award

    Dr. David Drewry at the Genetic Medicine Building on the campus of UNC-Chapel Hill .
    Research

    Collaborating for a Cure

    Drug treatments for a rare form of cancer have eluded researchers for years. Work at the UNC Eshelman School of Pharmacy has scientists and survivors optimistic that big breakthroughs are within reach.